Japanese Journal of Radiology

, Volume 36, Issue 11, pp 676–685 | Cite as

Post-marketing surveillance of gadobutrol for contrast-enhanced magnetic resonance imaging in Japan

  • Yoshito TsushimaEmail author
  • Kazuo Awai
  • Gen Shinoda
  • Hiroyuki Miyoshi
  • Masayuki Chosa
  • Toshiyuki Sunaya
  • Jan Endrikat
Special Report



To evaluate the safety of gadobutrol for magnetic resonance imaging in a prospective, non-interventional, post-marketing surveillance in Japan.

Materials and methods

Gadobutrol was administered in accordance with Japanese prescribing information over a 2-year enrollment period, using a standardized questionnaire to collect information. The primary outcome was the incidence of adverse reactions (ARs) following gadobutrol injection.


Questionnaire data were analyzed for 3337 patients (age, 58.1 ± 17.4 years [mean±SD]). Gadobutrol was administered at a dose of 0.10 ± 0.02 mL/kg body weight. Thirty-three patients were observed to have 42 ARs suspected to be due to gadobutrol, an incidence proportion of 0.99%; 29 ARs were acute (<1 h post-injection)—including one case of severe acute AR (0.03%). Patient subpopulations (with hepatic, renal, cardiovascular diseases) did not differ markedly in AR proportions categorized by age, sex, presence of comorbidity, or imaging indication. No cases of nephrogenic systemic fibrosis were reported. Investigators rated images as improved or profoundly improved following gadobutrol injection in 91.1% of examinations.


Gadobutrol was well tolerated with a good safety profile in this post-marketing surveillance of a large patient population in Japan.


Gadobutrol Gadolinium-based contrast agents Magnetic resonance imaging (MRI) Post-marketing surveillance 



This surveillance was funded by Bayer Yakuhin, Ltd. Editorial assistance was provided by Bill Wolvey of PAREXEL, which was funded by Bayer Yakuhin, Ltd.

Compliance with ethical standards

Conflict of interest

YT has no conflict of interest. KA received lecture fees and honoraria for chairman from Bayer Yakuhin, Ltd. GS is an employee of Bayer Yakuhin, Ltd. HM is an employee of Bayer Yakuhin, Ltd. MC is an employee of Bayer Yakuhin, Ltd. TS is an employee of Bayer Yakuhin, Ltd. JE is an employee of Bayer AG.

Ethical standards and informed consent

This surveillance was conducted in compliance with the GPSP and GVP of the Ministry of Health, Labor and Welfare in Japan. Approval by the ethics committee of each institution was not mandatory, since GPSP and GVP do not require such approval for a PMS. Informed consent from each patient was waived


  1. 1.
    Huppertz A, Rohrer M. Gadobutrol, a highly concentrated MR-imaging contrast agent: its physicochemical characteristics and the basis for its use in contrast-enhanced MR angiography and perfusion imaging. Eur Radiol. 2004;14(Suppl 5):M12–8.PubMedGoogle Scholar
  2. 2.
    Tombach B, Benner T, Reimer P, Schuierer G, Fallenberg EM, Geens V, et al. Do highly concentrated gadolinium chelates improve MR brain perfusion imaging? Intraindividually controlled randomized crossover concentration comparison study of 0.5 versus 1.0 mol/L gadobutrol. Radiology. 2003;226:880–8.CrossRefGoogle Scholar
  3. 3.
    Tombach B, Heindel W. Value of 1.0-M gadolinium chelates: review of preclinical and clinical data on gadobutrol. Eur Radiol. 2002;12:1550–6.CrossRefGoogle Scholar
  4. 4.
    Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann HJ. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol. 2005;40:715–24.CrossRefGoogle Scholar
  5. 5.
    Shen Y, Goerner FL, Snyder C, Morelli JN, Hao D, Hu D, et al. T1 relaxivities of gadolinium-based magnetic resonance contrast agents in human whole blood at 1.5, 3, and 7 T. Invest Radiol. 2015;50:330–8.CrossRefGoogle Scholar
  6. 6.
    Endrikat J, Vogtlaender K, Dohanish S, Balzer T, Breuer J. Safety of gadobutrol: results from 42 clinical phase II to IV studies and postmarketing surveillance after 29 million applications. Invest Radiol. 2016;51:537–43.CrossRefGoogle Scholar
  7. 7.
    Forsting M, Palkowitsch P. Prevalence of acute adverse reactions to gadobutrol—a highly concentrated macrocyclic gadolinium chelate: review of 14,299 patients from observational trials. Eur J Radiol. 2010;74:e186–92.CrossRefGoogle Scholar
  8. 8.
    Hahn G, Sorge I, Gruhn B, Glutig K, Hirsch W, Bhargava R, et al. Pharmacokinetics and safety of gadobutrol-enhanced magnetic resonance imaging in pediatric patients. Invest Radiol. 2009;44:776–83.CrossRefGoogle Scholar
  9. 9.
    Kunze C, Mentzel HJ, Krishnamurthy R, Fleck R, Stenzel M, Bhargava R, et al. Pharmacokinetics and safety of macrocyclic gadobutrol in children aged younger than 2 years including term newborns in comparison to older populations. Invest Radiol. 2016;51:50–7.CrossRefGoogle Scholar
  10. 10.
    Prince MR, Lee HG, Lee CH, Youn SW, Lee IH, Yoon W, et al. Safety of gadobutrol in over 23,000 patients: the GARDIAN study, a global multicentre, prospective, non-interventional study. Eur Radiol. 2017;27:286–95.CrossRefGoogle Scholar
  11. 11.
    Glutig K, Bhargava R, Hahn G, Hirsch W, Kunze C, Mentzel HJ, et al. Safety of gadobutrol in more than 1,000 pediatric patients: subanalysis of the GARDIAN study, a global multicenter prospective non-interventional study. Pediatr Radiol. 2016;46:1317–23.CrossRefGoogle Scholar
  12. 12.
    Voth M, Rosenberg M, Breuer J. Safety of gadobutrol, a new generation of contrast agents: experience from clinical trials and postmarketing surveillance. Invest Radiol. 2011;46:663–71.PubMedGoogle Scholar
  13. 13.
    Malik M, Hnatkova K, Schmidt A, Smetana P. Correction for QT/RR hysteresis in the assessment of drug-induced QTc changes—cardiac safety of gadobutrol. Ann Noninvasive Electrocardiol. 2009;14:242–50.CrossRefGoogle Scholar
  14. 14.
    Balzer JO, Loewe C, Davis K, Goyen M, Leiner T, Meaney JF, et al. Safety of contrast-enhanced MR angiography employing gadobutrol 1.0 M as contrast material. Eur Radiol. 2003;13:2067–74.CrossRefGoogle Scholar
  15. 15.
    Tombach B, Bremer C, Reimer P, Kisters K, Schaefer RM, Geens V, et al. Renal tolerance of a neutral gadolinium chelate (gadobutrol) in patients with chronic renal failure: results of a randomized study. Radiology. 2001;218:651–7.CrossRefGoogle Scholar
  16. 16.
    Frenzel T, Lengsfeld P, Schirmer H, Hutter J, Weinmann HJ. Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C. Invest Radiol. 2008;43:817–28.CrossRefGoogle Scholar
  17. 17.
    Sieber MA, Lengsfeld P, Frenzel T, Golfier S, Schmitt-Willich H, Siegmund F, et al. Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions. Eur Radiol. 2008;18:2164–73.CrossRefGoogle Scholar
  18. 18.
    Grobner T. Gadolinium—a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant. 2006;21:1104–8.CrossRefGoogle Scholar
  19. 19.
    Thomsen HS, Morcos SK, Almen T, Bellin MF, Bertolotto M, Bongartz G, et al. Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol. 2013;23:307–18.CrossRefGoogle Scholar
  20. 20.
    American College of Rheumatology. ACR Manual on Contrast Media. Version. 10.3. 2007.
  21. 21.
    European Medicines Agency. EMA./425304/2010. Rev.1. Patient Health Protection. 2010.
  22. 22.
    Kanda T, Oba H, Toyoda K, Kitajima K, Furui S. Brain gadolinium deposition after administration of gadolinium-based contrast agents. Jpn J Radiol. 2016;34:3–9.CrossRefGoogle Scholar
  23. 23.
    Cao Y, Huang DQ, Shih G, Prince MR. Signal change in the dentate nucleus on T1-weighted MR images after multiple administrations of gadopentetate dimeglumine versus gadobutrol. AJR Am J Roentgenol. 2016;206:414–9.CrossRefGoogle Scholar
  24. 24.
    Radbruch A, Haase R, Kieslich PJ, Weberling LD, Kickingereder P, Wick W, et al. No signal intensity increase in the dentate nucleus on unenhanced T1-weighted MR images after more than 20 serial injections of macrocyclic gadolinium-based contrast agents. Radiology. 2017;282:699–707.CrossRefGoogle Scholar
  25. 25.
    Radbruch A, Weberling LD, Kieslich PJ, Hepp J, Kickingereder P, Wick W, et al. High-signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted images: evaluation of the macrocyclic gadolinium-based contrast agent gadobutrol. Invest Radiol. 2015;50:805–10.CrossRefGoogle Scholar
  26. 26.
    Renz DM, Kumpel S, Bottcher J, Pfeil A, Streitparth F, Waginger M, et al. Comparison of unenhanced T1-weighted signal intensities within the dentate nucleus and the globus pallidus after serial applications of gadopentetate dimeglumine versus gadobutrol in a pediatric population. Invest Radiol. 2018;53:119–27.CrossRefGoogle Scholar
  27. 27.
    Schlemm L, Chien C, Bellmann-Strobl J, Dorr J, Wuerfel J, Brandt AU, et al. Gadopentetate but not gadobutrol accumulates in the dentate nucleus of multiple sclerosis patients. Mult Scler. 2017;23:963–72.CrossRefGoogle Scholar
  28. 28.
    Fingerhut S, Niehoff AC, Sperling M, Jeibmann A, Paulus W, Niederstadt T, et al. Spatially resolved quantification of gadolinium deposited in the brain of a patient treated with gadolinium-based contrast agents. J Trace Elem Med Biol. 2018;45:125–30.CrossRefGoogle Scholar
  29. 29.
    Kanda T, Fukusato T, Matsuda M, Toyoda K, Oba H, Kotoku J, et al. Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: Evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy. Radiology. 2015;276:228–32.CrossRefGoogle Scholar
  30. 30.
    Murata N, Gonzalez-Cuyar LF, Murata K, Fligner C, Dills R, Hippe D, et al. Macrocyclic and other non-group 1 gadolinium contrast agents deposit low levels of gadolinium in brain and bone tissue: preliminary results from 9 patients with normal renal function. Invest Radiol. 2016;51:447–53.CrossRefGoogle Scholar
  31. 31.
    Roberts DR, Welsh CA, LeBel DP 2nd, Davis WC. Distribution map of gadolinium deposition within the cerebellum following GBCA administration. Neurology. 2017;88:1206–8.CrossRefGoogle Scholar
  32. 32.
    Michaely HJ, Aschauer M, Deutschmann H, Bongartz G, Gutberlet M, Woitek R, et al. Gadobutrol in renally impaired patients: results of the GRIP study. Invest Radiol. 2017;52:55–60.CrossRefGoogle Scholar
  33. 33.
    European Society of Urogenital Radiology. ESUR guidelines on contrast media, Version 9.0. 2017.
  34. 34.
    Tsushima Y, Ishiguchi T, Murakami T, Hayashi H, Hayakawa K, Fukuda K, et al. Safe use of iodinated and gadolinium-based contrast media in current practice in Japan: a questionnaire survey. Jpn J Radiol. 2016;34:130–9.CrossRefGoogle Scholar
  35. 35.
    Imai E, Yasuda Y, Makino H. Japan Association of Chronic Kidney Disease Initiatives (J-CKDI). JMAJ. 2011;54:406–8.Google Scholar
  36. 36.
    Michel A, Abudulah A, Schumann W. Spontaneous reporting of adverse drug reactions: estimation of underreporting for contrast media reactions in 14 countries. Pharmacoepidemiol Drug Saf. 2001;10:34.Google Scholar
  37. 37.
    Weisbord SD, Mor MK, Resnick AL, Hartwig KC, Palevsky PM, Fine MJ. Incidence and outcomes of contrast-induced AKI following computed tomography. Clin J Am Soc Nephrol. 2008;3:1274–81.CrossRefGoogle Scholar
  38. 38.
    Soyer P, Dohan A, Patkar D, Gottschalk A. Observational study on the safety profile of gadoterate meglumine in 35,499 patients: The SECURE study. J Magn Reson Imaging. 2017;45:988–97.CrossRefGoogle Scholar
  39. 39.
    de Kerviler E, Maravilla K, Meder JF, Naggara O, Dubourdieu C, Jullien V, et al. Adverse reactions to gadoterate meglumine: review of over 25 years of clinical use and more than 50 million doses. Invest Radiol. 2016;51:544–51.CrossRefGoogle Scholar
  40. 40.
    Fakhran S, Alhilali L, Kale H, Kanal E. Assessment of rates of acute adverse reactions to gadobenate dimeglumine: review of more than 130,000 administrations in 7.5 years. AJR Am J Roentgenol. 2015;204:703–6.CrossRefGoogle Scholar
  41. 41.
    Abujudeh HH, Kosaraju VK, Kaewlai R. Acute adverse reactions to gadopentetate dimeglumine and gadobenate dimeglumine: experience with 32,659 injections. AJR Am J Roentgenol. 2010;194:430–4.CrossRefGoogle Scholar
  42. 42.
    Shellock FG, Parker JR, Venetianer C, Pirovano G, Spinazzi A. Safety of gadobenate dimeglumine (MultiHance): summary of findings from clinical studies and postmarketing surveillance. Invest Radiol. 2006;41:500–9.CrossRefGoogle Scholar
  43. 43.
    Matsumura T, Hayakawa M, Shimada F, Yabuki M, Dohanish S, Palkowitsch P, et al. Safety of gadopentetate dimeglumine after 120 million administrations over 25 years of clinical use. Magn Reson Med Sci. 2013;12:297–304.CrossRefGoogle Scholar
  44. 44.
    Ishiguchi T, Takahashi S. Safety of gadoterate meglumine (Gd-DOTA) as a contrast agent for magnetic resonance imaging: results of a post-marketing surveillance study in Japan. Drugs R D. 2010;10:133–45.CrossRefGoogle Scholar
  45. 45.
    Japan Radiological Society. Japanese College of Radiology. The Japanese Imaging Guideline. 2013.
  46. 46.
    Noda Y, Goshima S, Namimoto T, Shinkawa N, Nakagawa M, Kajita K, et al. Simultaneous acquisition of MR angiography and diagnostic images of abdomen at view-sharing multiarterial phases and comparing the effect of two different contrast agents. J Magn Reson Imaging. 2018;48:102–10.CrossRefGoogle Scholar

Copyright information

© Japan Radiological Society 2018

Authors and Affiliations

  • Yoshito Tsushima
    • 1
    Email author
  • Kazuo Awai
    • 2
  • Gen Shinoda
    • 3
  • Hiroyuki Miyoshi
    • 3
  • Masayuki Chosa
    • 4
  • Toshiyuki Sunaya
    • 5
  • Jan Endrikat
    • 6
    • 7
  1. 1.Department of Diagnostic Radiology and Nuclear MedicineGunma University Graduate School of MedicineMaebashiJapan
  2. 2.Department of Diagnostic Radiology, Graduate School of Biomedical and Health SciencesHiroshima UniversityHiroshimaJapan
  3. 3.Medical Affairs Radiology, Bayer Yakuhin, LtdOsakaJapan
  4. 4.Pharmacovigilance PMS, Bayer Yakuhin, LtdOsakaJapan
  5. 5.Product Development, Clinical StatisticsBayer Yakuhin, LtdOsakaJapan
  6. 6.RadiologyBayer AGBerlinGermany
  7. 7.Department of Gynecology, Obstetrics and Reproductive MedicineUniversity Medical School of SaarlandHomburg/SaarGermany

Personalised recommendations